Current Vascular Pharmacology
Title:Editorial: News in Cardiovascular Surgery Treatment: Is there Anything to do Before and After it?
Volume: 16 Issue: 4
Author(s): J.L. Guerrero Orriach and M. Ramirez-Aliaga
Affiliation:
Export Options
About this article
Cite this article as:
Orriach Guerrero J.L. and Ramirez-Aliaga M. , Editorial: News in Cardiovascular Surgery Treatment: Is there Anything to do Before and After it?, Current Vascular Pharmacology 2018; 16 (4) . https://dx.doi.org/10.2174/1570161116666180108101825
DOI https://dx.doi.org/10.2174/1570161116666180108101825 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Tachykinins and the Cardiovascular System
Current Drug Targets Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Galectin-1 is a Novel Factor that Regulates Myotube Growth in Regenerating Skeletal Muscles
Current Drug Targets The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents
Current Medicinal Chemistry - Central Nervous System Agents The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry The p38α Kinase Plays a Central Role In Inflammation
Current Topics in Medicinal Chemistry Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry